Related Experiment Video
Updated: Mar 2, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Immune checkpoint inhibitors in lung cancer: current status and future directions
1Department of Cancer Medicine (Thoracic), Zhejiang Cancer Hospital, Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology (Esophagus, Lung), Hangzhou 310022, China. fanyun@zjcc.org.cn.
Abstract:
Recently, the immune checkpoint inhibitors that target programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) have made a breakthrough in treating advanced non-small cell lung cancer (NSCLC) with the efficacy of approximately 20%; among which, nivolumab has acquired treatment indications in lung squamous cell carcinoma. The inhibitors targeting cytotoxic T lymphocyte associated antigen 4 (CTLA-4) are also undergoing clinical trials. Researches on immune checkpoint inhibitors have been rapidly implemented in a variety of different types of lung cancer, such as small cell lung cancer (SCLC) and locally advanced NSCLC, and these inhibitors began to be applied in combination with some established treatments, including chemotherapy, targeting therapy and radiotherapy. Undoubtedly, the immune checkpoint inhibitors have become a hot spot in the research and treatment of lung cancer. However, many problems wait to be solved, such as searching for ideal biomarkers, constituting the best criteria for curative effect evaluation, exploring different combination treatment models, and clearly understanding the mechanisms of primary or secondary drug resistance. Along with these problems to be successfully solved, the immune checkpoint inhibitors will have more broad applications in lung cancer therapy.
Insights
Immune checkpoint inhibitors targeting PD-1/PD-L1 show promise for advanced non-small cell lung cancer (NSCLC), with ongoing research exploring combinations and resistance mechanisms for broader lung cancer therapy applications.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have emerged as a significant advancement in treating advanced non-small cell lung cancer (NSCLC), demonstrating approximately 20% efficacy.
- Nivolumab, an ICI, is approved for lung squamous cell carcinoma, and CTLA-4 inhibitors are under clinical investigation.
Purpose of the Study:
- To review the current status and future directions of immune checkpoint inhibitors in lung cancer treatment.
- To highlight the challenges and opportunities in optimizing ICI therapy for various lung cancer subtypes.
Main Methods:
- Literature review of recent studies on immune checkpoint inhibitors in lung cancer.
- Analysis of clinical trial data and research trends in ICI therapy.
- Discussion of combination treatment strategies and resistance mechanisms.
Main Results:
- ICIs have shown efficacy in advanced NSCLC and are being investigated in small cell lung cancer (SCLC) and locally advanced NSCLC.
- Combination therapies involving ICIs with chemotherapy, targeted therapy, and radiotherapy are under active research.
- Significant challenges remain, including biomarker identification, efficacy evaluation criteria, optimal combination strategies, and understanding drug resistance.
Conclusions:
- Immune checkpoint inhibitors represent a rapidly evolving and crucial area in lung cancer research and treatment.
- Addressing current challenges is essential for expanding the therapeutic applications of ICIs in lung cancer.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...